Large enterprises 25.62%, 0.84%p ↓… medium-sized firms 34.36%, 1.24%p ↓
Small and medium-sized companies 2.72%p ↑, exceed the average 40%
The listed pharma companies’ sales were reduced in the aftermath of COVID-19, but their SG&A ratio has declined.
Newsmp aggregated November and December of 60 listed pharma enterprises’ semi-annual report and found out that the SG&A ratio of the second quarter recorded 29.04% below YoY, down about 0.72%p.
However, SME SG&A rallied, giving more burden for small enterprises.
Examine by the revenue size, the average SG&A of the over $100 billion companies was 25.62%, down 0.84%p YoY. $25 billion and $100 billion enterprises also lowered 1.24%p to 32.36%.
Meanwhile, the average SG&A ratio for SME (quarterly sales under $25 billion) is up 2.72%p to 41.73%.
By companies, SG&A was decreased for 35 enterprises while 25 firms rose.
Dongsung-Pharma’s SG&A cut down 14.05% for the most, as well as Korean Drug Co. 11.24%p.
DongKoo Bio & Pharma dropped about 10%, and Ahn-gook Pharma, Hyundai Pharma, ST Pharma, Bukwang Pharma, Korean United Pharma, Chong Kun Dang Pharma, and Shin Poong Pharma were down for more than 5%.
On the contrary, Union Korea Pharma’s SG&A soared 21.84%p, Samsung Pharma 18.67%p, MyungMoon Pharma 11.83%p, and Samchundang Pharma 11.80%p.
Sam-A Pharma, Hanall Biopharma, Daehwa Pharma, Yungjin Pharma, Kukje Pharma, Dong-A ST Co. BC World Pharma, and Reyon Pharma’s moved up above 5%.
The SG&A of MyungMoon Pharma in the second quarter solely surpassed 70% by 70.07%, followed by Union Korea Pharma 64.41%.
Reyon Pharma, Sam-A Pharma, Seoul Pharma, Samchundang Pharma, and Samsung Pharma exceeded 50%. Kukje Pharma, Arlico Pharma, Dong Kook Pharma, Hana Pharma, Jin Yang Pharma, Wooridul Pharma, DongKoo Bio & Pharma, Ahn-gook Pharma, JW Shinyak Corp, CMG Pharma, Yuyu Pharma, Huons Co., KyungDong Pharma, Choa Pharma, and Daewha Pharma are at 40%.
Daewon Pharma, Kyung Nam Pharma, Korea United Pharma, Hanall Biopharma, Dong-A ST Co. Ilsung Pharma, BC World Pharma, Yunghin Pharma, Dong Wha Pharma, Ildong Pharma, Sinsin Pharma, Samil Pharma, Shin Poong Pharma, Dongsung Pharma, JW Pharma Corp., Samjin Pharma, Il-Yang Pharma, and Daewoong Pharma remained at 30% SG&A ratio.
Hyundai Pharma, Boryung Pharma, Handok Pharma, Sinil Pharma, Bukwang Pharma, Kwang Dong Pharma, Green Cross Corp., Hanmi Pharma, Celltrion Pharma and Korean Drug Corp. stand at 20%.
Jeil Pharma, Aprogen Pharma, ST Pharma, Yuhan Corp., Daihan Pharma, Kyongbo Pharma, Chong Kun Dang Pharma, CKD Bio Corp., and JW Life Science Corp. are at 10% of SG&A ratio while Hwail Pharma is below 10%.
